Clive Baveghems
About Clive Baveghems
Dr. Clive Baveghems founded NanoLipomedics with the goal of advancing targeted and individualized delivery of anticancer drugs. His vision to create a library of high -density lipoprotein (HDL) anticancer nanocarriers is motivated by more than twenty years of analytical method development including more than a decade of protein engineering, more than eight years of HDL biophysical characterization, and more than seven years developing a novel HDL anticancer nanocarrier for targeted drug delivery. Over the years, he has established key collaborative relationships with deep knowledge in drug delivery, oncology, and finance who partner with NanoLipoMedics to advance individualized anticancer drug delivery to the clinic.
Dr. Baveghems is currently a Faculty Associate and Research Laboratory Manager at Massachusetts College of Pharmacy and Health Sciences. Prior to MCPHS, he was a biophysical characterization scientist at Charles River Laboratories. He was awarded a Ruth L. Kirschstein postdoctoral fellowship from the NIH for biophysical characterization of lipoprotein nanoparticles in the laboratory of Dr. Olga Gursky in the Whitaker Cardiovascular Institute at the Boston University School of Medicine.
Dr. Baveghems earned his PhD in chemistry from the University of Connecticut under the guidance of Dr. Challa V. Kumar. He earned his BSc in chemistry from the University of Maryland at College Park.